

David Michael Markovitz, M.D.
Professor, Internal Medicine/Infectious Diseases
1150 W. Medical Center Drive, 5220C MSRB III
Ann Arbor, MI 48109-5640
734-647-1786
dmarkov@umich.edu

Education and Training

June 1972	St. Louis Park High School, St. Louis Park, Minnesota
August 1976	University of Minnesota, Minneapolis, Minnesota, B.A.
June 1981	University of Minnesota, Minneapolis, Minnesota, M.D.
June 1981-June 1984	Residency, University of Rochester Associated Hospitals Program in Internal Medicine, Rochester, New York
June 1984-June 1986	Fellowship, Infectious Diseases Unit, Department of Internal Medicine, University of Rochester School of Medicine, Rochester, New York
July 1986-June 1988	Research Fellowship, Lineberger Cancer Center, Laboratory of Dr. Joseph S. Pagano, Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina

Certification and Licensure

1988-present	Michigan
1986-1988	North Carolina
1982-1988	New York
1986-present	American Board of Internal Medicine/Infectious Diseases Subspecialty
1984-present	American Board of Internal Medicine

Academic, Administrative, and Clinical Appointments

June 1988-August 1994	Assistant Professor, Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan
September 1994-Aug. 2002	Associate Professor (with tenure), Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan
September 2002-present	Professor (with tenure), Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan

Research Interests

- Role of the DEK oncoprotein in cancer and inflammation
- Human endogenous retroviruses/centromere biology
- Molecular engineering of antiviral lectins
- Human Immunodeficiency Viruses Types 1 and 2

Grants

Present and Active

Sponsor: National Institutes of Health (NIH)
Title: DEK Regulation of Hematopoietic Stem Cell Renewal, Fate, and Hematopoiesis
Co-PIs: David M. Markovitz and Hal Broxmeyer
Dates: 07/01/16 – 05/31/20
Funding Amount (total direct costs): \$578,075 (to Markovitz Laboratory)

Sponsor: University of Michigan Mi-Kickstart Award
Title: A Molecularly-Modified Lectin for the Treatment of Lung Cancer
PI: David Markovitz
Dates: 01/03/18 – 01/02/19
Funding Amount (total direct costs): \$42,500

Previous (since 2001)

Sponsor: American Cancer Society
Title: Mechanism of Action and Biological Effect of the DEK Oncoprotein
PI: David M. Markovitz
Dates: 07/01/98 – 06/30/01
Funding Amount: \$255,000

Sponsor: National Heart, Lung, and Blood Institute
Title: Chemokines and HIV Replication in Alveolar Macrophages
PI: Michael Coffey
Dates: 10/01/96 – 07/30/01
Role: Co-PI
Funding Amount: \$460,000

Sponsor: National Cancer Institute
Title: Great Lakes Regional Center for AIDS Research
PI: Steven Wolinsky
Dates: 09/01/98 – 08/31/01
Role: Co-investigator
Funding Amount: \$183,000

Sponsor: Arthritis Foundation
Title: Expression of DEK in Macrophages: Implications for JRA
PI: Nirit Mor-Vaknin
Dates: 07/01/00 – 06/30/02
Role: Mentor to Dr. Nirit Mor-Vaknin, Postdoctoral Fellow
Funding Amount: \$70,000

Sponsor: National Institute of Allergy and Infectious Diseases
Title: Regulation of HIV-2 Transcription and Replication
PI: David M. Markovitz
Dates: 07/15/98 – 06/30/03
Funding Amount: \$986,679

Sponsor: Arthritis Foundation
Title: Role of DEK in JRA
PI: David M. Markovitz
Dates: 01/01/01 – 12/31/03
Funding Amount: \$250,000

Sponsor: National Institute of Allergy and Infectious Diseases

Title: C-X-C Chemokines and HIV Pathogenesis
PI: David M. Markovitz
Dates: 9/30/04 – 04/14/05
Funding Amount: \$135,000

Sponsor: University of Michigan Comprehensive Cancer Center Prostate Spore Pilot Project
Title: Role of Secreted Vimentin in the Pathogenesis of Prostate Cancer
PI: David M. Markovitz
Dates: 06/01/04 – 05/31/05
Funding Amount: \$50,000

Sponsor: National Heart, Lung, and Blood Institute
Title: C-X-C Chemokines and Kaposi's Sarcoma
PI: David M. Markovitz
Dates: 07/01/01 – 05/31/07
Funding Amount: \$1,000,000

Sponsor: MI Institute for Clinical and Health Research
Title: Use of HERV-K (HML-2) as a Biomarker for Lymphoma and Breast Cancer
PI: Scott D. Gitlin
Dates: 10/01/07 – 09/30/08
Role: Co-Investigator
Funding Amount (Markovitz): \$35,000

Sponsor: Burroughs Wellcome Fund
Title: Clinical Scientist Award in Translational Research
PI: David M. Markovitz
Dates: 01/01/04 – 12/31/08
Funding Amount: \$750,000

Sponsor: UMHS Faculty Group Practice Board of Directors
Title: DEK as a Biomarker in JRA/JIA
PI: Barbara S. Adams
Dates: 09/01/08 – 08/31/09
Role: Co-Investigator
Funding Amount (Markovitz): \$11,500

Sponsor: National Institute of Allergy and Infectious Diseases
Title: C-X-C Chemokines and HIV Pathogenesis
PI: David M. Markovitz
Dates: 04/15/05 – 12/31/09
Funding Amount: \$1,115,000

Sponsor: Arthritis Foundation
Title: Posttranslational Modifications of DEK and Their Role in Autoimmunity
PI: Ferdinand Kappes
Dates: 07/01/06 – 06/30/10
Role: Mentor
Funding Amount (total direct costs): \$150,000

Sponsor: Michigan Institute for Clinical and Health Research
Title: The Role of DEK in the Development of Arthritis
PI: Nirit Mor-Vaknin
Dates: 07/01/08 – 06/30/10
Role: Mentor
Funding Amount (total direct costs): \$100,000

Sponsor: Michigan Institute for Clinical and Health Research
Title: The DEK Oncoprotein as a Therapeutic Target in Melanoma
PI: David M. Markovitz
Dates: 09/01/09 – 08/31/10
Funding Amount (total direct costs): \$50,000

Sponsor: University of Michigan GI Peptide Research Center
Title: The Function of Vimentin in the Development of Chronic Gut Inflammation
PI: Nirit Mor-Vaknin
Dates: 09/01/09 – 08/31/10
Role: Mentor
Funding Amount (total direct costs): \$25,000

Sponsor: National Institutes of Health
Title: Curcumin: A Multimechanism HIV Microbicide
PI: Raju C. Reddy
Dates: 09/25/08 – 08/31/10
Role: Co-Investigator
Funding Amount (Markovitz): \$25,000 in total direct costs to the Markovitz laboratory

Sponsor: Novartis Vaccines and Diagnostics
Title: The Endogenous Retrovirus HERV-K as a Cancer Biomarker
PI: David M. Markovitz
Dates: 06/01/09 – 06/30/11
Funding Amount (total direct costs): \$55,000

Sponsor: Michigan Institute for Clinical and Health Research
Title: The DEK Oncoprotein as a Therapeutic Target in Melanoma
PI: David M. Markovitz
Dates: 09/01/09 – 08/31/10
Funding Amount (total direct costs): \$50,000
Sponsor: University of Michigan GI Peptide Research Center
Title: The Function of Vimentin in the Development of Chronic Gut Inflammation
PI: Nirit Mor-Vaknin
Dates: 09/01/09 – 08/31/10
Role: Mentor
Funding Amount (total direct costs): \$25,000

Sponsor: National Institutes of Health
Title: Curcumin: A Multimechanism HIV Microbicide
PI: Raju C. Reddy
Dates: 09/25/08 – 08/31/10
Role: Co-Investigator

Funding Amount (Markovitz): \$25,000 in total direct costs to the Markovitz laboratory
Sponsor: Novartis Vaccines & Diagnostics
Title: HERV-K and Prostate Cancer
PI: David M. Markovitz
Dates: 12/06/10 – 12/05/11
Funding Amount (total direct costs): \$43,260

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Title: DEK and TNF Inhibitors in Juvenile Arthritis
PI: David M. Markovitz
Dates: 09/01/09 – 08/31/13
Funding Amount (total direct costs): \$1,000,000

Sponsor: NIH/NCI (Research Supplement to Promote Diversity in Health-Related Research)
Title: Replication of Endogenous Retroviruses in Modern Humans
PI: David M. Markovitz (for Rafael Contreras-Galindo)
Dates: 09/01/12 – 08/31/13
Funding Amount (total direct costs): \$82,609

Sponsor: National Institutes of Health
Natural Product-Inspired Method for Enhancing HIV Protease Inhibitors
PI: Jason Gestwicki
Dates: 02/01/12 – 01/31/14
Role: Co-investigator
Funding Amount: \$23,540 in total direct costs to the Markovitz Laboratory

Sponsor: National Institutes of Health (K01 award)
Title: The Role of DEK in the Development of Arthritis
PI: Nirit Mor-Vaknin
Dates: 07/01/09 – 05/31/14
Role: Mentor
Funding Amount (total direct costs): \$490,000

Sponsor: National Institutes of Health (F32)
Title: The Viral Life Cycle of Human Endogenous Retrovirus Type K
PI: Derek Dube
Dates: 06/10/13 – 06/09/14
Role: Mentor
Funding Amount (total direct costs): \$169,218

Sponsor: National Institutes of Health
Title: Biological Activity of Lead Compounds Targeting HIV-1 TAR RNA
Co-PI: David M. Markovitz and Hashim Al-Hashimi
Dates: 08/01/12 – 07/31/14
Funding Amount: \$145,422 in total direct costs to the Markovitz Laboratory

Sponsor: National Institutes of Health
Title: Targeting HIV-1 Regulatory RNA Elements
PI: Hashim Al-Hashimi
Dates: 04/01/10 – 03/31/15
Role: Co-Investigator
Funding Amount: \$79,710 in total direct costs to the Markovitz Laboratory

Sponsor: Office of the Director, NIH/NCI (Transformative R01 Program)
Title: Replication of Endogenous Retroviruses in Modern Humans
PI: David M. Markovitz
Dates: 09/28/09 – 08/31/15
Funding Amount (total direct costs): \$4,473,469

Sponsor: University of Michigan Technology Transfer Office (Kickstart Award)
Title: Treatment of Influenza with H84T
PI: David M. Markovitz
Dates: 05/01/15 – 04/30/16
Funding Amount (total direct costs): \$39,000

Sponsor: NIH/NCI (Transition Career Development Award to Promote Diversity K22)
Title: Human Endogenous Retroviral Sequences, a Tool to Study the Role of Centromeres in Human Cancer
PI: Rafael Contreras-Galindo
Dates: 09/23/13 – 08/31/16
Role: Mentor
Funding Amount (total direct costs): \$346,389

Sponsor: University of Michigan MTRAC Life Sciences
Title: Treatment of Influenza with a New Broad-Spectrum Antiviral Agent
PI: David M. Markovitz
Dates: 02/01/16 – 04/30/17
Funding Amount (total direct costs): \$259,291

Sponsor: Defense Threat Reduction Agency (DTRA)
Title: A Molecularly-Engineered Lectin for Use as a Treatment for Ebola and Marburg Viruses
PI: David M. Markovitz
Dates: 09/01/15 – 02/12/18
Funding Amount (total direct costs): \$850,000

Sponsor: Rheumatology Research Foundation
Title: DEK in the Pathogenesis and Treatment of JIA
PI: David M. Markovitz
Dates: 07/01/15 – 06/30/18
Funding Amount (total direct costs): \$400,000

Sponsor: UM Israel Partnership for Research and Education
Title: What Makes a Human Brain or What Makes a Brain Human
Co-PIs: David Markovitz and Orly Reiner
Dates: 07/17/17 – 06/30/18
Funding Amount (total direct costs): \$50,000

Sponsor: MTRAC AgBio Tier II Starter Award
Title: DEK Aptamer for the Treatment of Equine Acute and Chronic Joint Inflammation
PI: David Markovitz
Dates: 04/01/18-10/01/18
Funding Amount (total direct costs): \$26,876

Sponsor: University of Hong Kong
Title: Efficacy and Mechanistic Evaluation of Banana Lectin (BanLec) as a Novel Pan-coronavirus Antiviral Agent: In-vitro and Ex-vivo Evidence
PI: Jasper Chan
Dates: 12/06/16 – 12/05/18
Funding Amount (total direct costs to Markovitz Laboratory): \$16,667

Honors and Awards

1976 University of Minnesota, B.A., Magna Cum Laude
1990 National Cancer Institute - Clinical Investigator Award
1991 Life and Health Insurance Medical Research Fund Scholar
1997 American Society for Clinical Investigation
2003 Burroughs Wellcome Fund Clinical Scientist Award in Translational Research
2004 Association of American Physicians
2009 Transformative R01, Office of the Director, NIH
2012 American Clinical and Climatological Association

Memberships in Professional Societies

American Society for Microbiology
American Association for the Advancement of Science
Infectious Diseases Society of America
American Society for Clinical Investigation
Association of American Physicians
American Clinical and Climatological Association

Editorial Positions, Boards, and Peer-Review Service

Editorial Board

Journal of Virology
2002-2007

Ad Hoc Reviewer (Journals)

AIDS Research and Human Retroviruses

Blood

Journal of Clinical Investigation

Journal of Biological Chemistry

Clinical Infectious Diseases

Journal of Virology

Journal of Infectious Diseases

Proceedings of the National Academy of
Sciences, USA

Nature Chemical Biology

Virology

Nature Immunology

Molecular and Cellular Biology

Cancer Research

Journal of Molecular Evolution

PLoS Genetics

Science

Virology

Ad Hoc Reviewer (Grants)

Veterans' Administration Medical Centers

National Science Foundation

National Institutes of Health

Food and Drug Administration

Teaching

Clinical Teaching

Instruction of medical students and Infectious Diseases fellows in the outpatient clinic (previously)

Instruction of medical students, residents, and Infectious Diseases fellows on Infectious Diseases Consult Service (1-2 months/year)

Selected Undergraduate Students

Laboratory research mentor for Ms. Amruta Mundade, Ms. Anna Tavakkoli, Mr. Nilesh Shah, Ms. Kim Guo, Mr. Bahbak Shariat-Madar, and Mr. Anjan Saha. (Dr. Shah is now an Internal Medicine faculty member at UCSD, Dr. Guo is in Internal Medicine practice at the University of Michigan, Dr. Tavakkoli is now a gastroenterology fellow at the University of Michigan, the late Ms. Mundade was accepted into the University of Michigan Medical School, Mr. Shariat-Madar is now a medical student at the University of Pittsburgh, and Mr. Saha is now in the MSTP at the University of Michigan.) The recent undergraduate students in the laboratory were Yue (Anna) Yu (now a graduate student in Public Health at the University of Michigan), Miguel Rivas (now a graduate student at Wayne State University), and Patrick Cervantes (PREP program; now a graduate student at the University of Wisconsin). Claire Wang, a high school student, is now an undergraduate at Stanford. Emily Gitlin is a high school student presently working in the laboratory.

Master's Students

Ayesha Khan, Department of Epidemiology, School of Public Health, University of Michigan

Amalie Dick, University of Konstanz, Germany (now a Ph.D. student in Munich, Germany)

Anran Wang, Department of Epidemiology, School of Public Health, University of Michigan (now a medical student at the University of Michigan)

Yuanfan (Cynthia) Ye, Department of Epidemiology, School of Public Health, University of Michigan (now a Ph.D. student at the University of Alabama at Birmingham)

Sabrina Fischer Alpuin, Faculty of Science – University of the Republic, Uruguay (now a Ph.D. student at Institut Pasteur in Montevideo)

Auroni Gupta, Department of Epidemiology, School of Public Health, University of Michigan

Medical Students in Laboratory

Pre-clinical advisor and laboratory mentor for Ms. Juliet Mavromatis (Dr. Mavromatis is now an Internal Medicine faculty member at Emory University)

Laboratory research instruction for Ms. Kristin Robinson, medical student, for which she won the AOA Award for Best Research by a Medical Student (Dr. Robinson is now a faculty member at the University of California at Davis)

Laboratory research instruction for Ms. Lisa Bodley (Dr. Sprague [Bodley] is now a pediatrician at IHA Pediatric Healthcare Associates, Canton, MI)

Laboratory research instruction for Mr. Sia Dahi (General Surgery)

Laboratory research instruction for Mr. Joseph Wollman (currently a faculty member in Emergency Medicine at Wayne State University)

Laboratory research instruction for Ms. Elisa Quiroz (currently a fourth-year medical student at the Ponce School of Medicine)

Laboratory research instruction for Ms. Maria Del Mar Morales (currently a second-year medical student at the Ponce School of Medicine)

Ph.D. Preliminary Examination Committees

Sin-Hang Chan, Department of Microbiology and Immunology

Eric Humke, Cellular and Molecular Biology Program

Yifei Wu, Cellular and Molecular Biology Program

Irfan Lodhi, Cellular and Molecular Biology Program

Kelly Seidl, Immunology Program

Vilasack Thammavongsa, Immunology Program

Eric Komuniecki, Immunology Program

Travis Maures, Cellular and Molecular Biology Program

Matthew Pratt-Hyatt, Cellular and Molecular Biology Program

Adam MacNeil, Harvard School of Public Health

Elizabeth Wonderlich, Cellular and Molecular Biology Program

Elisabeth Starnes, Cellular and Molecular Biology Program

Morgan Penny, Cancer Biology Program

Doctoral Thesis Committees

Liqian Zhang, Department of Biological Chemistry

Wei Zhu, Department of Anatomy and Cell Biology

Evelisse Gonzalez, Cellular and Molecular Biology Program

Yifei Wu, Cellular and Molecular Biology Program

Narayani Moorthy, Cellular and Molecular Biology Program

Ping Ye, Department of Microbiology and Immunology

Mojgan Naghavi, Karolinska Institute, Stockholm, Sweden

Jennifer Fuller, Program in Immunology

Jennifer McGregor, Program in Immunology

Tamara Tucker, Cellular and Molecular Biology Program

Ron Merhavi, School of Music

Christoph Carter, Cellular and Molecular Biology Program

Kevin Vannella, Program in Immunology

Matt Klinker, Program in Immunology

Bradley R. Jones, Graduate Department of Immunology, University of Toronto

David Collins, Program in Immunology

Laboratory Research Instruction for Internal Medicine Residents

Dr. Vivian Lin (now Senior Director at Rockwell Medical)

Dr. William Geisler (now a Professor of Infectious Diseases at the University of Alabama)

Dr. Emily Wong (now an Infectious Diseases physician)

Dr. Jeffery Anderson (now Clinical Assistant Professor at the University of North Carolina)

Dr. Rajan RaviKumar (now an Assistant Professor of Internal Medicine at the University of Michigan)

Dr. Emily Shuman (now an Assistant Professor of Internal Medicine at the University of Michigan)

Dr. Zachery Reichert (now a Hematology/Oncology Fellow at the University of Michigan)

Post-Doctoral Fellows

Nina Clark, M.D., Infectious Diseases Fellow (now a Professor of Medicine at Loyola University, Chicago)

John Hilfinger, Ph.D. (the late Dr. Hilfinger was the President of TSRL)

Igho Oforokun, M.D., Infectious Diseases Fellow (now a Professor of Medicine at Emory University)

Joanne Cleary, Ph.D. (previously a scientist in the Department of Obstetrics and Gynecology at the University of Michigan)

Nirit Mor-Vaknin, Ph.D. (now a Research Assistant Professor at the University of Michigan)

Ferdinand Kappes, Ph.D. (now a Junior Group Leader at the Institute of Biochemistry and Molecular Biology, RWTH Aachen University)

Sarah Cookinham, M.D. (now in the private practice of Infectious Diseases)

Rafael Contreras-Galindo, Ph.D. (now a Research Assistant Professor at the University of Michigan)

Dan Boudreaux, Ph.D. (now a scientist with the United States Army)

Derek Dube, Ph.D. (now an Assistant Professor at St. Joseph's University)

Robert Woods, M.D., Ph.D. (now an Assistant Professor at the University of Michigan)

Ph.D. Advisor

Glenn Fu, School of Public Health (Winner of the Third Annual (1994) Prize for Student Research from the Department of Epidemiology); (a founder and senior scientist at Cellular Research)

Catherine Browning, Department of Microbiology and Immunology (now a medical writer)

Neil Faulkner, Cellular and Molecular Biology Program, Medical Scientist Training Program (currently an Oncologist at the University of Tennessee in Knoxville)

Brian Lane, Cellular and Molecular Biology Program, Medical Scientist Training Program (won prize for outstanding research by a graduating medical student, 2002); (currently a Urologist with Spectrum Health Medical Group and Clinical Associate Professor at Michigan State University)

Kajal Sitwala, Cellular and Molecular Biology Program, Medical Scientist Training Program (currently a Hematopathologist at the Marshfield Clinic)

Michael Khodadoust, Immunology Program, Medical Scientist Training Program (currently an Assistant Professor of Hematology/Oncology at Stanford University)

Michael Swanson, Immunology Program (currently a consultant at Merck)

Marta Gonzalez, Immunology Program (currently a scientist at Rubicon Genomics)

Susana Chan (Cellular and Molecular Biology Program)

Anjan Saha (MSTP; Cancer Biology)

Evelyn Coves-Datson (MSTP; Microbiology and Immunology)

Committee, Organizational, and Volunteer Service

Biosafety Level 3 Facility Committee, University of Michigan Medical Center, 1989-present

Search Committee for Director of Infection Control/Infectious Diseases faculty member, Department of Internal Medicine, 1991

Pharmacy and Therapeutics Committee, University of Michigan Hospitals, 1991-1999

Organizing Committee, Advances in Internal Medicine Course, Department of Internal Medicine, Spring of 1989 and 1992

Washtenaw County AIDS Task Force, Washtenaw County Michigan, 1993-1994

Virology Search Committee, University of Michigan School of Public Health, 1994-1995

Seminar Organizing Committee, Organogenesis Center, 1996-1999

Chair of Seminar Organizing Committee, Organogenesis Center, 1997-1999

Antibiotic Subcommittee, University of Michigan Hospitals, 1996-1999

Cellular and Molecular Biology 850 Lecture Series Organizing Committee, 1997-2004

Steering Committee, Molecular Mechanisms of Microbial Pathogenesis Training Program, 1998-2015

Organizer, Virology Research Group, 1996-2001

Epidemiology Search Committee, School of Public Health, 2001-2003

Infectious Diseases Faculty Search Committee, 2001-present; Chair, 2014-present

University of Michigan Medical School Admissions Committee, 2003-2007

Search Committee for Chair, Department of Biological and Material Sciences, University of Michigan Dental School, 2004

Graduate Student Affairs Committee, Program in Immunology, 2007-2010

Board of Directors, American Physician Scientists Association, 2012-present

Research Committee, Infectious Diseases Society of America, 2009-2014; Chair, 2011-2014

Selection Committee, Cancer Biology Program at the University of Michigan, 2013-present

Provost's Faculty Advisory Committee, University of Michigan, 2013-2015

Search Committee for Chief, Division of Rheumatology, University of Michigan, 2017-2018

Consulting Positions

FDA Vaccines and Related Biological Products Advisory Committee, 2002-2006

Novartis Vaccines, 2007-2014

GSK Vaccines, 2017-present

Visiting Professorships, Seminars, and Extramural Invited Presentations (since 1998)

“Regulation of Retroviral Transcription by Cellular Factors”
Infectious Diseases Seminar Series
Memorial Sloan-Kettering Cancer Center
New York, New York
January 1998

“Regulation of HIV-2 Transcription”
Seminar Series, Harvard School of Public Health
Boston, Massachusetts
February 1998

“Regulation of HIV-2 Transcription”
Co-organizer and Speaker
Keystone Symposium: “HIV Pathogenesis and Treatment”
Park City, Utah
March 1998

“Regulation of HIV-2 Transcription by Intriguing Cellular Factors”
Molecular Medicine Series
Oregon Health Sciences University
Portland, Oregon
May 1998

“Regulation of HIV-2 Transcription by Intriguing Cellular Factors”
Seminar Series, University College
London, England
June 1998

“Regulation of HIV-2 Transcription by Intriguing Cellular Factors”
Molecular and Cellular Biology Seminar, Arizona State University
Tempe, Arizona
October 1998

“Regulation of HIV-2 Transcription”
Department of Virology Seminar Series
Karolinska Institute, Stockholm, Sweden
October 1998

“HIV-2 Infection”
University of Lisbon
Lisbon, Portugal
October 1998

“Regulation of HIV-2 Transcription by Cellular Factors”
Second ICGEB Virology Symposium
New Delhi, India
November 1998

“Infection with HIV-2”
Internal Medicine Grand Rounds
University of Illinois at Chicago
Chicago, Illinois
December 1998

"Regulation of HIV-2 Transcription by Intriguing Cellular Factors"
Internal Medicine Research Conference
Tulane University
New Orleans, Louisiana
April 1999

"GLI-2 Synergizes with Tat to Activate HIV Transcription"
International Symposium on HIV, Leukemia, & Opportunistic Cancers
Marrakesh, Morocco
May 1999

"Regulation of HIV Transcription by Intriguing Cellular Factors"
City of Hope Medical Center
Duarte, California
July 1999

"Regulation of HIV Replication by Intriguing Cellular Factors"
University of the Virgin Islands
St. Thomas, Virgin Islands
February 2000

"Regulation of HIV Transcription"
San Marino Conference on Immunology, Oncology, and Virology
Republic of San Marino
June 2000

"Regulation of HIV Transcription and Replication"
New Jersey Medical School
Newark, New Jersey
October 2000

"Regulation of HIV by Intriguing Cellular Factors"
University of California at Irvine
Irvine, California
November 2000

"The Role of IL-8 and GRO- α in HIV Replication"
GlaxoSmithKline
Philadelphia, Pennsylvania
January 2001

"IL-8, Gro- α , and Kaposi's Sarcoma"
University of Minnesota Dental School
Minneapolis, Minnesota
February 2001

"HIV and Cellular Factors"
Harvard School of Public Health
Boston, Massachusetts
April 2001

"DEK Expression is Regulated by PP2A"
Indiana University Cancer Center Symposium
Indianapolis, Indiana
April 2001

“Regulation of DEK Expression”
4th International Conference on Gene Regulation, Oncogenesis, and AIDS
Athens, Greece
September 2002

“Regulation of DEK Expression”
Université Libre de Bruxelles
Brussels, Belgium
October 2002

“Adventures with the Exotic DEK Protein”
Department of Biochemistry, University of Minnesota
Minneapolis, Minnesota
April 2003

“Adventures with the Exotic DEK Protein”
Johns Hopkins Medical School, Department of Molecular Pharmacology
Baltimore, Maryland
September 2003

“Regulation of HIV Transcription by Intriguing Cellular Factors”
Meeting of the Institute of Human Virology
Baltimore, Maryland
October 2003

“Adventures with the Exotic DEK Protein”
University of Konstanz
Konstanz, Germany
October 2003

“AIDS”
University of Seville
Seville, Spain
October 2003

“The Role of IL-8 and GRO- α in HIV Replication”
Department of Pathology, Stanford University
Palo Alto, California
January 2004

“Adventures with the Exotic DEK Protein”
Laboratory of Dr. Robin Reed, Harvard Medical School
Boston, Massachusetts
February 2004

“Regulation of HIV Replication by Cellular Factors”
Committee on Microbiology, University of Chicago
Chicago, Illinois
May 2004

“The Role of IL-8 and GRO- α in HIV Replication”
Meeting of the Institute of Human Virology
Baltimore, Maryland
October 2004

“Adventures with the Exotic DEK Protein: in the Footsteps of HMGB1”
LIJ Institute for Medical Research
Manhasset, New York
January 2005

“IL-8, GRO- α , and HIV Replication”
North Shore University Hospital
Manhasset, New York
January 2005

“The Role of DEK in Inflammation”
Pontificia Universidad Católica De Puerto Rico
Ponce, Puerto Rico
April 2005

“Prosthetic Joint Infections”
Texas Tech Health Sciences Center
Lubbock, Texas
September 2005

“Adventures with the Exotic DEK Protein”
Chiron Vaccine Research Center
Siena, Italy
October 2005

“The DEK Autoantigen is a Secreted Chemotactic Factor”
Eli Lilly and Company
Indianapolis, Indiana
November 2005

“Adventures with DEK”
Emory University
Atlanta, Georgia
March 2006

“Exploiting HIV to Dissect Cellular Mechanisms”
University of Alabama
Birmingham, Alabama
June 2006

“Adventures with the DEK Autoantigen”
University of North Carolina
Chapel Hill, North Carolina
October 2006

“The Role of Vimentin in Microbial Pathogenesis”
Novartis Vaccines
Siena, Italy
November 2006

“Endogenous Retroviruses”
bioMerieux Global Research and Development
Grenoble, France
February 2007

“Unexpected Chemokines Emerging from Studies of HIV”
Weizmann Institute
Rehovot, Israel
June 2007

“Adventures at the Interface Between Virus and Cell”
University of Miami, Department of Internal Medicine
Miami, Florida
September 2007

“The Exotic DEK Protein Modulates Chromatin Structure”
Centre de Regulacio Genomica
Barcelona, Spain
October 2007

“The Secret Life of the Human Endogenous Retrovirus HERV-K”
Karolinska Institute
Stockholm, Sweden
December 2007

“The Secret Life of the Human Endogenous Retrovirus HERV-K”
University of Wisconsin
Madison, Wisconsin
April 2008

“The Secret Life of a Human Endogenous Retrovirus”
Istituto Scientifico Universitario San Raffaele
Milan, Italy
October 2008

“The Human Endogenous Retrovirus HERV-K”
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
March 2009

“The Secret Life of the Endogenous Retrovirus HERV-K”
University of Cincinnati
Cincinnati, Ohio
May 2009

“The Secret Life of an Endogenous Retrovirus”
Blood Systems Research Institute/UCSF
San Francisco, California
July 2009

“Human Endogenous Retroviruses as Cancer Biomarkers”
Ninth Frye Halloran Symposium on Neuro-Oncology
Massachusetts General Hospital
Boston, Massachusetts
November 2009

“The Secret Life of a Human Endogenous Retrovirus”
University of Toledo
Toledo, Ohio
March 2010

“Human Endogenous Retroviruses and Cancer”
Novartis Vaccines
Siena, Italy
June 2010

“DEK: A Most Unusual Pro-Inflammatory Factor”
National Eye Institute/NIH
Bethesda, Maryland
September 2010

“Do Human Endogenous Retroviruses Replicate in Modern Humans?”
Institute of Human Virology Annual Meeting
Tropea, Italy
October 2010

“Molecular Engineering of a Banana Lectin that Inhibits HIV Replication”
Novartis Vaccines & Diagnostics
Cambridge, Massachusetts
November 2010

“The Surprising Life of a Human Endogenous Retrovirus”
Mount Sinai School of Medicine
New York, New York
December 2010

“The Secret Life of a Human Endogenous Retrovirus”
Colorado State University
Fort Collins, Colorado
April 2011

“The Surprising Life of a Human Endogenous Retrovirus”
Institut für Biochemie und Molekularbiologie, Universitätsklinikum Aachen
Aachen, Germany
May 2011

“DEK: Trying to Connect the Dots”
Mini Symposium: The chromatin architectural factor DEK: an “Epigenetic” Oncoprotein?
Universität Konstanz
Konstanz, Germany
May 2011

“The Secret Life of a Human Endogenous Retrovirus”
Robert Koch Institute
Berlin, Germany
May 2011

“Vaccines: Very Successful, Strangely Controversial”
Institute on Science for Global Policy
La Jolla, California
June 2011

“The Exotic DEK Oncoprotein: A Key Factor in Heterochromatin Integrity”
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois
September 2011

“The Secret Life of a Human Endogenous Retrovirus”
Graduate Department of Immunology
University of Toronto
December 2011

“How to Write Grants”
Speaker and Organizer
NIAID/IDSA Research Careers Meeting
Bethesda, Maryland
May 2012

“Molecular Engineering of an Antiviral Lectin”
Rega Institute
Leuven, Belgium
October 2012

“The Secret Life of a Human Endogenous Retrovirus”
Michale E. Keeling Center for Comparative Medicine and Research
MD Anderson Cancer Center, University of Texas
Bastrop, Texas
March 2013

“The DEK Oncoprotein: A Secreted Regulator of Heterochromatin”
Stanford Cancer Center
Palo Alto, California
October 2013

“HIV Infection Reveals Wide-Spread Expansion of Novel Centromeric Human Endogenous Retroviruses”
American Clinical and Climatological Association
Charleston, South Carolina
October 2013

“Glyco-Engineering, Anti-Viral Agents, and *Esquire*”
Midwest Regional Meeting, American Physician Scientists Association
Columbus, Ohio
November 2013

“Molecular Engineering of a Banana Lectin”
Emory University Center for AIDS Research
Atlanta, Georgia
March 2014

“DEK, a Most Unusual Regulator of Chromatin, Inflammation, and Hematopoiesis”
Department of Microbiology, University of Indiana
Indianapolis, Indianapolis
June 2014

“A Molecularly-Engineered Antiviral Lectin, or How We Came to be Quoted in *Esquire*”
Department of Biochemistry, Duke University
Durham, North Carolina
September 2014

“Transformative, but not the Way We Thought: Adventures with Centromere Biology”
NIH meeting for High-Risk, High-Reward grant recipients
Bethesda, Maryland
December 2014

“The Np9 Protein from HERV-K and Brain Development”
Laboratory of Professor Orly Reiner, Weizmann Institute
Rehovot, Israel
January 2015

“Finding and Developing Career Mentors”
Panelist and Organizer
NIAID/IDSA Research Careers Meeting
Bethesda, Maryland
June 2015

“Adventures with the Exotic DEK Protein: A New Approach to the Treatment of Arthritis”
Lowance Center for Human Immunology, Emory University
Atlanta, Georgia
June 2015

“The Secret Life of Human Endogenous Retroviruses”
Second Latin American Conference on Virology
Buenos Aires, Argentina
June 2015

“The Clandestine Marriage of Human Endogenous Retroviruses and Centromeres”
Universidad de la República
Montevideo, Uruguay
July 2015

“Engineering a Therapeutic Lectin: Uncoupling Mitogenicity from Antiviral Activity”
The Rockefeller University
New York, New York
October 2015

“Engineering a Therapeutic Lectin: Uncoupling Mitogenicity from Antiviral Activity”
Saint Louis University
St. Louis, Missouri
March 2016

“Adventures with Human Endogenous Retroviruses and Centromeres, the Wild West of Genomics”
Roswell Park Cancer Institute
Buffalo, NY
March 2016

“An Antiviral Agent Derived from Bananas”
International Centre for Genetic Engineering and Biotechnology (ICGEB)
Trieste, Italy
September 2016

“An Antiviral Agent Derived from Bananas”
Institut Pasteur
Rome, Italy
September 2016

“How we Developed an Antiviral Lectin and then Made it More Alluring”
Keynote Speaker for Northwestern University Department of Microbiology Retreat
Lake Geneva, Wisconsin
October 2016

“Molecular Engineering of a Banana Lectin: Separating Mitogenicity from Antiviral Activity”
GSK Vaccines
Siena, Italy
March 2017

“Adventures with the Exotic DEK Protein: Immunity and Autoimmunity”
GSK Vaccines
Siena, Italy
March 2017

“Journey to the Centromere”
Weizmann Institute Department of Molecular Genetics
Rehovot, Israel
December 2017

“A Molecular Engineering Approach to Influenza Therapy”
Internal Medicine Division, University of Texas MD Anderson Cancer Center
Houston, Texas
January 2018

“Endogenous Retroviral Guided Journey to the Centromere”
National Institute of Neurological Disorders and Stroke, National Institutes of Health
Bethesda, Maryland
March 2018

“The Role of DEK in JIA”
Investigators’ Meeting, Rheumatology Research Foundation
San Francisco, California
June 2018

“Towards a Broad Spectrum Antiviral Agent: Sweet Stuff”
Department of Microbiology and Immunology, Indiana University School of Medicine
Indianapolis, Indiana
October 2018

“Attacking Viruses and Cancers with a Genetically Engineered Banana Lectin”
Infectious Diseases, Infection Control and Employee Health, University of Texas MD Anderson
Cancer Center
Houston, Texas
October 2018

“Attacking Viruses and Cancers with a Genetically Engineered Banana Lectin”
Karolinska Institute
Stockholm, Sweden
November 2018

Patents

1. Methods for Inhibition of HIV Replication Using a Small Molecule Inhibitor
U.S. #7,052,676
Date of Issue: November 3, 2005
2. Methods of Secretory Vimentin Detection and Modulation
U.S. #7,691,582
Date of Issue: April 6, 2010
3. Compositions and Methods for Detecting Cancer for Inhibiting Metastasis
U.S. #7,641,902
Date of Issue: January 5, 2010
4. DEK Protein Compositions and Methods of Using the Same
U.S. #8,652,467
Date of Issue: February 18, 2014
5. Lectins and Uses Thereof
U.S. # 8,865,867, B2
Date of Issue: October 21, 2014; also issued in Europe and in China
6. Inhibitors of DEK Protein and Related Methods
U.S. #15/557,757
Date of Issue: Fall 2018 (pending)

Bibliography

Peer-Reviewed Journals and Publications

1. Markovitz, D.M., Beutner, K.R., Maggio, R.P., and Reichman, R.C. Failure of recommended treatment for secondary syphilis. *JAMA* 1986; 255(13):1767-1768.
2. Gartner, S., Markovits, P., Markovitz, D.M., Kaplan, M.H., Gallo, R.C., and Popovic, M. The role of mononuclear phagocytes in HTLV-III/LAV infection. *Science* 1986; 233:215-219.
3. Gartner, S., Markovits, P., Markovitz, D.M., Betts, R.F., and Popovic, M. Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. *JAMA* 1986; 256(17):2365-2371.
4. Hall, C.B., Dolin, R., Gala, L.C., Markovitz, D.M., Zhang, Y.C., Madore, P.H., Disney, F.A., Talpey, W.B., Green, J.L., Francis, A.B., and Pichichero, M.E. Children with Influenza A infection: treatment with Rimantadine. *Pediatrics* 1987; 80(2):275-282.
5. Kenney, S., Kamine, J., Markovitz, D.M., Fenrick, R., and Pagano, J.S. An Epstein-Barr virus immediate-early gene product *trans*-activates gene expression from the human immunodeficiency virus long terminal repeat. *Proc. Natl. Acad. Sci. USA* 1988; 85:1652-1656.
6. Kenney, S., Kamine, J., Holley-Guthrie, E., Mar, E.C., Lin, J.C., Markovitz, D., and Pagano, J. The EBV immediate-early gene product, BMLF1, acts in *trans* by a posttranscriptional mechanism which is reporter gene dependent. *J. Virol.* 1989; 63(9):3870-3877.
7. Markovitz, D.M., Kenney, S., Kamine, J., Smith, M.S., Davis, M., Huang, E-S., Rosen, C., and Pagano, J.S. Disparate effects of two Herpesvirus immediate-early gene *trans*-activators on the HIV-1 LTR. *Virology* 1989; 173:363-367.
8. Markovitz, D.M., Hannibal, M., Perez, V.L., Gauntt, C., Folks, T.M., and Nabel, G.J. Differential regulation of human immunodeficiency viruses (HIVs): a specific regulatory element in HIV-2 responds to stimulation of the T-cell antigen receptor. *Proc. Natl. Acad. Sci. USA* 1990; 87:9098-9102.
9. Markovitz, D.M., Hannibal, M.C., Smith, M.J., Cossman, R., and Nabel, G.J. Activation of the human immunodeficiency virus type 1 enhancer is not dependent on NFAT-1. *J. Virol.* 1992; 66(6):3961-3965.
10. Wertheim, W.A. and Markovitz, D.M. Osteomyelitis and intervertebral discitis caused by *Pseudomonas picketti*. *J. Clin. Microbiol.* 1992; 30(9):2506-2508.
11. Markovitz, D.M., Smith, M.J., Hilfinger, J., Hannibal, M.C., Petryniak, B., and Nabel, G.J. Activation of the human immunodeficiency virus type 2 enhancer is dependent on purine box and κ B regulatory elements. *J. Virol.* 1992; 66(9):5479-5484.
12. Leiden, J.M., Wang, C-Y., Petryniak, B., Markovitz, D.M., Nabel, G.J., and Thompson, C.B. A novel ets-related transcription factor, Elf-1, binds to the human immunodeficiency virus type 2 regulatory elements that are required for inducible *trans*-activation in T cells. *J. Virol.* 1992; 66(10):5890-5897.
13. Chenoweth, C.E., Singal, S., Pearson, R.D., Betts, R.F., and Markovitz, D.M. AIDS-related visceral leishmaniasis presenting in a pleural effusion. *Chest* 1993; 103:648-649.
14. Markovitz, D.M. Infection with the human immunodeficiency virus type 2. *Ann. Intern. Med.* 1993; 118(3):211-218.

15. Eck, S.L., Morse, J.H., Janssen, D.A., Emerson, S.G., and Markovitz, D.M. Angioedema presenting as chronic gastrointestinal symptoms. *Amer. J. Gastroenterol.* 1993; 88(3):436-439.
16. Hilfinger, J.M., Clark, N., Smith, M., Robinson, K., and Markovitz, D.M. Differential regulation of the human immunodeficiency virus type 2 enhancer in monocytes at various stages of differentiation. *J. Virol.* 1993; 67(7):4448-4453.
17. Hannibal, M.C., Markovitz, D.M., Clark, N., and Nabel, G.J. Differential activation of HIV Type 1 and 2 transcription by specific T-cell activation signals. *J. Virol.* 1993; 67(8):5035-5040.
18. Clark, N.M., Smith, M.J., Hilfinger, J., and Markovitz, D.M. Activation of the human T-cell leukemia virus type I enhancer is mediated by binding sites for Elf-1 and the p63 factor. *J. Virol.* 1993; 67(9):5522-5528.
19. Mitchell, M.A., Markovitz, D.M., Killen, P.D., and Braun, D.K. Bilateral renal malacoplakia presenting as fever of unknown origin: case report and review. *Clin. Infect. Dis.* 1994; 18:704-718.
20. Hannibal, M.C., Markovitz, D.M., and Nabel, G.J. Multiple cis-acting elements in the human immunodeficiency virus type 2 enhancer mediate the response to T-cell receptor stimulation by antigen in a T-cell hybridoma line. *Blood* 1994; 83(7):1839-1846.
21. Walling, D.M., Clark, N.M., Markovitz, D.M., Frank, T.S., Braun, D.K., Eisenberg, E., Krutchkoff, D.J., Felix, D.H., and Raab-Traub, N. Epstein-Barr virus coinfection and recombination in non-human immunodeficiency virus-associated oral hairy leukoplakia. *J. Infect. Dis.* 1995; 171:1122-1130.
22. Clark, N.M., Hannibal, M.C., and Markovitz, D.M. The peri- κ B site mediates human immunodeficiency virus type 2 enhancer activation in monocytes but not T cells. *J. Virol.* 1995; 69(8):4854-4862.
23. Revankar, S. G., Applegate, A.L., and Markovitz, D.M. Delirium associated with acyclovir treatment in a patient with renal failure. *Clin. Infect. Dis.* 1995; 21:435-436.
24. Lin, V.H., Parekh, R.S., McQuillan, M.A., Braun, D.K., and Markovitz, D.M. Meningococcal endocarditis presenting as cellulitis. *Clin. Infect. Dis.* 1995; 21:1023-1025.
25. Fu, G.K. and Markovitz, D.M. Purification of the p63 factor. *J. Biol. Chem.* 1996; 271(32):19599-19605.
26. Fu, G.K., Smith, M.J., and Markovitz, D.M. Bacterial Protease Lon is a site-specific DNA-binding protein. *J. Biol. Chem.* 1997; 272(1):534-538.
27. Fu, G.K., Grosveld, G., and Markovitz, D.M. DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the human immunodeficiency virus type 2 enhancer. *Proc. Natl. Acad. Sci., USA* 1997; 94:1811-1815.
28. Coffey, M.J., Woffendin, C., Phare, S.M., Strieter, R.M., and Markovitz, D.M. RANTES inhibits HIV-1 replication in human peripheral blood monocytes and alveolar macrophages. *Am. J. Physiol.* 1997; 272:L1025-L1029.
29. Browning, C., Hilfinger, J.M., Rainier, S., Lin, V., Hedderwick, S., Smith, M., and Markovitz, D.M. The sequence and structure of the 3' arm of the first stem-loop of the human immunodeficiency virus type 2 trans-activation responsive region mediate Tat-2 transactivation. *J. Virol.* 1997; 71(10):8048-8055.
30. Geisler, W.M. and Markovitz, D.M. Septic arthritis caused by *Neisseria Sicca*. *J. Rheumatol.* 1998; 25:826-828.

31. Fu, G.K. and Markovitz, D.M. The human LON protease binds to mitochondrial promoters in a single-stranded, site-specific, strand-specific manner. *Biochemistry* 1998; 37(7):1905-1909.
32. Clark, N.M., Dieng-Sarr, A., Sankalé, J.-L., Kanki, P.J., Kazanjian, P., Winfield, R., and Markovitz, D.M. Immunologic and virologic response of HIV-2 infection to antiretroviral therapy. *AIDS* 1998; 12(18):2506-2507.
33. Browning, C.M., Cagnon, L., Good, P.D., Rossi, J., Engelke, D.R., and Markovitz, D.M. Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 Tat activation response RNA decoy. *J. Virol.* 1999; 73(6):5191-5195.
34. Lane, B.R., Markovitz, D.M., Woodford, N.L., Rochford, R., Strieter, R.M., and Coffey, M.J. TNF- α inhibits HIV-1 replication in peripheral blood monocytes and alveolar macrophages by inducing the production of RANTES and decreasing C-C chemokine receptor 5 (CCR5) expression. *J. Immunol.* 1999; 163:3653-3661.
35. Ofotokun, I., Carlson, C., Gitlin, S.D., Elta, G., Singleton, T.P., and Markovitz, D.M. Acute cytomegalovirus infection complicated by vascular thrombosis: a case report. *Clin. Infect. Dis.* 2001; 32:983-986.
36. Browning, C.M., Smith, M.J., Clark, N.M., Lane, B.R., Parada, C., Montano, M., KewalRamani, V.N., Littman, D.R., Essex, M., Roeder, R.G., and Markovitz, D.M. Human GLI-2 is a Tat activation response element-independent Tat cofactor. *J. Virol.* 2001; 75(5):2314-2323.
37. Smith, M.J., Gitlin, S.D., Browning, C.M., Lane, B.R., Clark, N.M., Shah, N., Rainer, S., and Markovitz, D.M. GLI-2 modulates retroviral gene expression. *J. Virol.* 2001; 75(5):2301-2313.
38. Lane, B.R., Strieter, R.M., Coffey, M.J., and Markovitz, D.M. Human immunodeficiency virus type 1 (HIV-1)-induced GRO- α production stimulates HIV-1 replication in macrophages and T lymphocytes. *J. Virol.* 2001; 75(13):5812-5822.
39. Faulkner, N.E., Hilfinger, J.M., and Markovitz, D.M. Protein phosphatase 2A activates the HIV-2 promoter through enhancer elements that include the pets site. *J. Biol. Chem.* 2001; 276(28):25804-25812.
40. Lane, B.R., Lore, K., Bock, P.J., Andersson, J., Coffey, M.J., Strieter, R.M., and Markovitz, D.M. Interleukin-8 stimulates human immunodeficiency virus type 1 replication and is a potential new target for antiretroviral therapy. *J. Virol.* 2001; 75(17):8195-8202.
41. Hayes, M.M., Lane, B.R., King, S.R., Markovitz, D.M., and Coffey, M.J. Peroxisome proliferator-activated receptor gamma agonists inhibit HIV-1 replication in macrophages by transcriptional and post-transcriptional effects. *J. Biol. Chem.* 2002; 277(19):16913-16919.
42. Hayes, M. M., Lane, B.R., King, S.R., Markovitz, D.M., and Coffey, M.J. Prostaglandin E₂ inhibits replication of HIV-1 in macrophages through activation of protein kinase A. *Cell. Immunol.* 2002; 215:61-71.
43. Lane, B.R., Liu, J., Bock, P.J., Schols, D., Coffey, M.J., Strieter, R.M., Polverini, P.J., and Markovitz, D.M. IL-8 and GRO- α mediate angiogenesis in Kaposi's Sarcoma. *J. Virol.* 2002; 76(22):11570-11583.
44. Sitwala, K.V., Adams, K., and Markovitz, D.M. YY1 and NF-Y binding sites regulate transcriptional activity of the dek and dek-can promoter. *Oncogene* 2002; 21:8862-8870.
45. Lane, B.R., King, S.R., Bock, P.J., Strieter, R.M., Coffey, M.J., and Markovitz, D.M. The C-X-C chemokine IP-10 stimulates HIV-1 replication. *Virology* 2003; 307:122-134.

46. Mor-Vaknin, N., Punturieri, A., Sitwala, K., and Markovitz, D.M. Vimentin is secreted by activated macrophages. *Nat. Cell Biol.* 2003; 5:59-63.
47. Faulkner, N.E., Lane, B.R., Bock, P.J., and Markovitz, D.M. Protein phosphatase 2A enhances activation of HIV-1 by PMA. *J. Virol.* 2003; 77(3):2276-2281.
48. Adams, B.S., Cha, C.C., Cleary, J., Tan, H., Wang, H., Sitwala, K., and Markovitz, D.M. DEK binding to class II MHC Y-box sequences is gene-and allele-specific. *Arthritis Research and Therapy* 2003; 5(4):R226-R233.
49. Xu, B., deWaal, R.M., Mor-Vaknin, N., Hibbard, C., Markovitz, D.M., and Kahn, M.L. The endothelial cell-specific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature. *Mol. Cell. Biol.* 2004; 24(20):9198-9206.
50. Cleary, J., Sitwala, K.V., Khodadoust, M.S., Kwok, R.P.S., Mor-Vaknin, N., Cebrat, M., Cole, P.A., and Markovitz, D.M. p300/CBP-associated factor drives DEK into interchromatin granule clusters. *J. Biol. Chem.* 2005; 280(36):31760-31767.
51. Malani, P.N., Read, J., Rees, R.S., and Markovitz, D.M. Beyond antimicrobials: a review of adjunctive therapies for pressure ulcers in older adults. *Infectious Diseases in Clinical Practice* 2006; 14(6): 345-349.
52. Contreras-Galindo, R., Kaplan, M.H., Markovitz, D.M., Lorenzo, E., and Yamamura, Y. Detection of HERV-K(HML-2) viral RNA in plasma of HIV Type 1-infected individuals. *AIDS Res. Hum. Retroviruses* 2006; 22(10):979-984.
53. Mor-Vaknin, N., Punturieri, A., Sitwala, K., Faulkner, N., Legendre, M., Khodadoust, M.S., Kappes, F., Ruth, J.H., Koch, A., Glass, D., Petruzzelli, L., Adams, B.S., and Markovitz, D.M. The DEK nuclear autoantigen is a secreted chemotactic factor. *Mol. Cell. Biol.* 2006; 26(24):9484-9496.
54. Bargagna-Mohan, P., Hamza, A., Kim, Y., Ho, Y.K., Mor-Vaknin, N., Wendschlag, N., Liu, J., Evans, R.M., Markovitz, D.M., Zhan, C-G., Kim, K.B., and Mohan, R. The tumor inhibitor and anti-angiogenic agent Withaferin A targets the intermediate filament protein vimentin. *Chemistry and Biology* 2007; 14(6):623-634.
55. Bielinska, A.U., Janczak, K.W., Landers, J.J., Markovitz, D.M., Montefiori, D.C., and Baker, J.R., Jr. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV-1 isolates. *AIDS Res. Hum. Retroviruses* 2008; 24(2):271-281.
56. Devany, M., Kappes, F., Chen, K-M., Markovitz, D.M., and Matsuo, H. Solution NMR structure of the N-terminal domain of the human DEK protein. *Protein Sci.* 2008; 17:205-215. PMID: PMC2222715.
57. Kappes, F., Fahrer, J., Khodadoust, M.S., Tabbert, A., Strasser, C., Mor-Vaknin, N., Moreno-Villanueva, M., Burkle, A., Markovitz, D.M., and Ferrando-May, E. DEK is a poly(ADP-ribose)-acceptor in apoptosis and mediates resistance to genotoxic stress. *Mol. Cell. Biol.* 2008; 28(10):3245-3257. PMID: PMC2423161.
58. Contreras-Galindo, R., Kaplan, M.H., Leissner, P., Verjat, T., Ferlenghi, I., Bagnoli, F., Giusti, F., Dosik, M.H., Hayes, D.F., Gitlin, S.D., and Markovitz, D.M. Human Endogenous Retrovirus-K (HML-2) elements in the plasma of people with lymphoma and breast cancer. *J. Virol.* 2008; 82(19):9329-9336. PMID: PMC2546968.
59. Khodadoust, M.S., Verhaegen, M., Kappes, F., Riveiro-Falkenbach, E., Cigudosa, J.C., Kim, D.S.L., Chinnaiyan, A.M., Markovitz, D.M.*, and Soengas, M.S*. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. *Cancer Res.* 2009; 69(16):6405-6413. PMID: PMC2727675.

60. McDowell, K.L., Begley, L.A., Mor-Vaknin, N., Markovitz, D.M., and Macoska, J.A. Leukocytic promotion of prostate cellular proliferation. *The Prostate* 2010; 70:377-389. PMID: PMC3167472.
61. Swanson, M.D., Winter, H.C., Goldstein, I.J., and Markovitz, D.M. A lectin isolated from bananas is a potent inhibitor of HIV replication. *J. Biol. Chem.* 2010; 285(12):8646-8655. PMID: PMC2838287.
62. Fahrner, J., Popp, O., Malanga, M., Beneke, S., Markovitz, D.M., Ferrando-May, E., Burkle, A., and Kappes, F. High affinity interaction of poly (ADP-ribose) and the human DEK oncoprotein depends upon chain length. *Biochemistry* 2010; 49(33):7119-7130. PMID: PMC2929705.
63. Dai, M., Thompson, R., Maher, C., Contreras, R., Kaplan, M., Markovitz, D., Omenn, G., and Meng, F. NGSQC: Cross-platform quality analysis pipeline for deep sequencing data. *BMC Genomics* 2010; 11 Suppl 4:S7. PMID: PMC3005923.
64. Mor-Vaknin, N., Kappes, F., Dick, A.E., Legendre, M., Damoc, C., Teitz-Tennenbaum, S., Kwok, R., Ferrando-May, E., Adams, B.S., and Markovitz, D.M. DEK in the synovium of JIA patients: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen. *Arthritis Rheum.* 2011; 63(2):556-567. PMID: PMC3117121.
65. Kappes, F., Waldmann, T., Mathew, V., Yu, J., Zhang, L., Khodadoust, M.S., Chinnaiyan, A.M., Luger, K., Erhardt, S., Schneider, R., and Markovitz, D.M. The DEK oncoprotein is a su(var) that is essential to heterochromatin integrity. *Genes Dev.* 2011; 25:673-678. PMID: PMC3070930.
66. Kappes F., Khodadoust, M.S., Yu, L., Kim, D.S.L., Fullen, D.R., Markovitz D.M., and Ma, L. DEK expression in melanocytic lesions. *Hum. Path.* 2011; 42(7):932-8. PMID: PMC3162348.
67. Stelzer, A.C., Frank, A. T., Kratz, J.D., Swanson, M., Gonzalez-Hernandez, M.J., Lee, J., Andricioaei, I., Markovitz, D.M., and Al-Hashimi, H.M. Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble. *Nat. Chem. Bio.* 2011; 7:553-559. PMID: PMC3319144.
68. Ferir, G., Vermeire, K., Huskens, D., Balzarini, J., Van Damme, E.J., Kehr, J., Dittmann, E., Swanson, M.D., Markovitz, D.M., and Schols, D. Synergistic in vitro anti-HIV activity of tenofovir with carbohydrate-binding agents (CBAs). *Antiviral Res.* 2011; 90(3):200-4.
69. Broxmeyer, H., Kappes, F., Mor-Vaknin, N., Legendre, M., Kinzfohl, J., Cooper, S., Hangoc, G., and Markovitz, D. DEK regulates hematopoietic stem engraftment and progenitor cell proliferation. *Stem Cells Dev.* 2012; 21(9):1449-54. PMID: PMC3359622.
70. Contreras-Galindo, R.A., Kaplan, M.H., Contreras-Galindo, A.C., Gonzalez-Hernandez, M., Ferlengui, I., Giusti, F., Lorenzo, E., Gitlin, S.D., Dosik, M.H., Yamamura, Y., and Markovitz, D.M. Characterization of human endogenous retroviral elements in the blood of HIV-1-infected individuals. *J. Virol.* 2012; 86(1):262-76. PMID: PMC3255917.
71. Gonzalez-Hernandez, M.J., Swanson, M.D., Contreras-Galindo, R., Cookinham, S., King, S.R., Noel, R.J. Jr., Kaplan, M.H., and Markovitz, D.M. Expression of Human Endogenous Retrovirus Type-K (HML-2) is activated by the Tat protein of HIV-1. *J. Virol.* 2012; 86(15):7790-7805. PMID: PMC3421662.
72. Ferir, G., Huskens, D., Palmer, K.E., Boudreaux, D.M., Swanson, M.M., Markovitz, D.M., Balzarini, J., and Schols, D. Combinations of griffithsin with other carbohydrate-binding agents (CBAs) demonstrate superior activity against HIV-1, HIV-2 and selected CBA-resistant HIV-1 strains. *AIDS Res Hum Retroviruses* 2012; 28(11):1513-23. PMID: PMC3484736.
73. Patel, R.M., Walters, L.L., Kappes, F., Mehra, R., Fullen, D.R., Markovitz, D.M., and Ma, L. DEK expression in Merkel cell carcinoma and small cell carcinoma. *J. Cutan. Pathol.* 2012; 39(8):753-7.

74. Monde, K., Contreras-Galindo, R., Kaplan, M.H., Markovitz, D.M., and Ono, A. HERV-K Gag coassembles with HIV-1 Gag and reduces the release efficiency and infectivity of HIV-1. *J. Virol.* 2012; 86(20):11194-208. PMID: PMC3457174.
75. Mor-Vaknin, N., Legendre, M., Yue, Y., Serezani, C.H.C., Garg, S.K., Jatzek, A., Swanson, M.D., Gonzalez-Hernandez, M.J., Teitz-Tennenbaum, S., Punturieri, A., Engleberg, N.C., Banerjee, R., Peters-Golden, M., Kao, J.Y., and Markovitz, D.M. Murine colitis is mediated by vimentin. *Sci. Rep.* 2013; 3:1045. PMID: PMC3540396.
76. Saha, A.K., Kappes, F., Mundade, A., Deutzmann, A., Rosmarin, D., Legendre, M., Chatain, N., Al-Obaidi, Z., Adams, B.S., Ploegh, H., Ferrando-May, E., Mor-Vaknin, N.*, and Markovitz, D.M.* Intercellular trafficking of the nuclear oncoprotein DEK. *Proc. Natl. Acad. Sci., USA.* 2013; 110(17):6847-52. PMID: PMC3637753.
77. Contreras-Galindo, R., Kaplan, M.H., He, S., Contreras-Galindo, A.C., Gonzalez-Hernandez, M.J., Kappes, F., Dube, D., Chan, S.M., Robinson, D., Meng, F., Dai, M., Gitlin, S.D., Chinnaiyan, A.M., Omenn, G.S. and Markovitz, D.M. HIV infection reveals wide-spread expansion of novel centromeric human endogenous retroviruses. *Genome Res.*, 2013; 23(9):1505-13. PMID: PMC3759726.
78. Broxmeyer, H.E., Mor-Vaknin, N., Kappes, F., Legendre, M., Saha, A.K., Ou, X., O'Leary, H.A., Capitano, M., Cooper, S., and Markovitz, D.M. A role for DEK in stem/progenitor cell biology. *Stem Cells*, 2013; 31(8):1447-53. PMID: PMC3814160.
79. Gonzales-Hernandez, M.J., Cavalcoli, J.D., Sartor, M.A., Contreras-Galindo, R., Fan, M., Manhong, D., Dube, D., Saha, A.K., Gitlin, S.C., Omenn, G.S., Kaplan, M.H., and Markovitz, D.M. Regulation of the Human Endogenous Retrovirus K (HML-2) transcriptome by the HIV-1 Tat protein. *J. Virol.*, 2014. Aug;88(16):8924-35. PMID: 24872592.
80. Dube, D., Contreras-Galindo, R., He, S., King, S.R., Gonzalez-Hernandez, M.J., Gitlin, S.D., Kaplan, M.H., and Markovitz, D.M. Genomic flexibility of Human Endogenous Retrovirus type K. *J. Virol.*, 2014. Sep;88(17):9673-82. PMID: 24920813.
81. Logan, G.E., Mor-Vaknin, N., Braunschweig, T., Jost, E., Schmidt, P.V., Markovitz, D.M., Mills, K.I., Kappes, F., and Percy, M.J. DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML). *Blood Cells, Molecules, and Diseases*, 2014. DOI: 10.1016/j.bcmd.2014.07.009.
82. Zahn J., Kaplan M.H., Fischer S., Dai M., Meng F., Saha A.K., Cervantes P., Chan S., Dube D., Omenn G.S., Markovitz D.M.*, and Contreras-Galindo R. Expansion of a novel endogenous retrovirus throughout the pericentromeres of modern humans. *Genome Biology*. 2015 Apr 12;16(1):74. PMID: 25886262.
83. Contreras-Galindo R., Kaplan M.H., Dube D., Gonzalez-Hernandez M., Chan S., Meng F., Dai M., Omenn G.S., and Markovitz D.M. Human Endogenous Retrovirus type-K (HERV-K) virus particles package and transmit HERV-K-related sequences. *J. Virol.* 2015 Jul;89(14):7187-201. PMID: 25926654.
84. Swanson, M.D., Boudreaux, D.M., Salmon, S., Chugh, J., Winter, H.C., Meagher, J.L., Andre, S., Murphy, P.V., Oscarson, S., Roy, R., King, S., Kaplan, M.H., Goldstein, I.J., Tarbet, E.B., Hurst, B.L., Smee, D.F., de la Fuente, C., Hoffman, H-H., Xue, Y., Rice, C.M., Schols, D., Garcia, J.V., Stuckey, J.A., Gabius, H-J., Al-Hashimi, H.M., and Markovitz, D.M. Engineering a therapeutic lectin: uncoupling mitogenicity from antiviral activity. *Cell*. 2015 Oct 22;163(3):746-58. PMID: 26496612.

85. Russo, B. C., Stamm, L. M., Raaben, M., Kim, C. M., Kahoud, E., Robinson, L.R., Bose, S., Queiroz, A. L., Herrera, B. B., Baxt, L.A., Mor-Vaknin, N., Fu, Y., Molina, G., Markovitz, D. M., Whelan, S. P., and Goldberg, M. B. Intermediate filaments enable pathogen docking to trigger type 3 effector translocation. *Nat Microbiol.* 2016 Mar 7;1:16025. PMID: 27572444.
86. Huang, S. H., Chi, F., Peng, L., Bo, T., Zhang, B., Wu, X., Mor-Vaknin, N., Markovitz, D. M., Cao, H., and Zhou, Y.-H. Vimentin, a novel NF- κ B regulator, is required for meningitic *Escherichia coli* K1-induced pathogen invasion and PMN transmigration across the blood-brain barrier. *PLoS One.* 2016 Sep 22;11(9):e0162641. doi: 10.1371/journal.pone.0162641. PMID: 27657497.
87. Xiao, Q., Wang, Z., Williams, D., Leowanawat, P., Peterca, M., Sherman, S. E., Zhang, S., Hammer, D. A., Heiney, P. A., King, S. R., Markovitz, D. M., André, S., Gabius, H.-J., Klein, M. L., and Percec, V. Why Do Membranes of Some Unhealthy Cells Adopt a Cubic Architecture? *ACS Cent Sci.* 2016 Dec 28;2(12):943-953. doi: 10.1021/acscentsci.6b00284. Epub 2016 Dec 5. PMID: 28058284.
88. Mor-Vaknin, N., Saha, A., Legendre, M., Carmona-Rivera, C., Amin, M.A., Rabquer, B.J., Gonzales-Hernandez, M.J., Jorns, J., Mohan, S., Yalavarthi, S., Pai, D.A., Angevine, K., Imburg, S.J., Knight, J.S., Adams, B.S., Koch, A.E., Fox, D.A., Engelke, D.R., Kaplan, M.J., and Markovitz, D.M. DEK-Targeting DNA Aptamers as Therapeutics for Inflammatory Arthritis. *Nat Commun.* 2017 Feb 6;8:14252. doi: 10.1038/ncomms14252. PMID: 28165452.
89. Contreras-Galindo, R., Dube, D., Fujinaga, K., Kaplan, M., and Markovitz, D.M. Susceptibility of Human Endogenous Retrovirus Type-K to Reverse Transcriptase Inhibitors. *J. Virol.* 2017 Sep 20. pii: JVI.01309-17. doi: 10.1128/JVI.01309-17. PMID: 28931682.
90. Contreras-Galindo, R., Fischer, S., Saha, A.K., Lundy, J.D., Cervantes, P.W., Mourad, M., Wang, C., Qian, B., Dai, M., Meng, F., Chinnaiyan, A., Omenn, G.S., Kaplan, M.H., and Markovitz, D.M. Rapid Molecular Assays to Study Human Centromere Genomics. *Genome Res.* 2017 Dec;27(12):2040-2049. doi: 10.1101/gr.219709.116. Epub 2017 Nov 15. PMID: 29141960.
91. Mor-Vaknin, N., Rivas, M., Legendre, M., Mohan, S., Yuanfan, Y., Mau, T., Johnson, A., Huang, B., Zhao, L., Kimura, Y., Spalding, S., Morris, P., Gottlieb, B.S., Onel, K., Olson, J.C., Edelheit, B., Shishov, M., Jung, L., Cassidy, E., Prahalad, S., Passo, M., Beukelman, T., Mehta, J., Giannini, E.H., Adams, B.S., Lovell, D.J., and Markovitz, D.M. High Levels of DEK Autoantibodies in Sera of Polyarticular JIA Patients and in Early Flare Following Cessation of Anti-TNF Therapy. *Arthritis & Rheumatology.* 2018 Apr;70(4):594-605. doi: 10.1002/art.40404. Epub 2018 Feb 22. PMID: 29287303.
92. Ghosha, P., Halvorsen, E. M., Ammendolia, D. A., Mor-Vaknin, N., O'Riordan, M. X. D., Brumell, J. H., Markovitz, D. M., and Higgins, D. E. Invasion of the Brain by *Listeria Monocytogenes* is Mediated by InlF and Host Cell Vimentin. *mBio.* 2018 Feb 27;9(1). pii: e00160-18. doi: 10.1128/mBio.00160-18. PMID: 29487235
93. Hacker, K., Bolland, D., Tan, L., Saha, A., Niknafs, Y., Markovitz, D., McLean, K. The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival. *Neoplasia* 2018. *In Press.*

* Equal contribution